Overview

TriPRIL CAR T Cells in Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. - TriPRIL CAR T Cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Phase:
Phase 1
Details
Lead Sponsor:
Marcela V. Maus, M.D.,Ph.D.
Treatments:
Cyclophosphamide
Fludarabine